Navigation Links
MediciNova Announces Positive Clinical Results From MN-166 Phase II,Multiple Sclerosis Trial

Conference Call to Discuss Results On Thursday, March 29, 2007, At 2:00 p.m. Pacific Time

SAN DIEGO, March 27, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced positive clinical findings from the 12-month core period of a Phase II clinical trial of MN-166 that measures both surrogate (radiological) and clinical outcomes over two years of treatment in 297 patients with relapsing multiple sclerosis (MS).

The randomized, double-blind, placebo-controlled trial showed a significant increase in the proportion of patients who remained relapse-free over the first 12 months of treatment with 60 mg per day of MN-166 compared to placebo (p=0.03). The time to first relapse was also significantly increased in patients treated with 60 mg of MN-166 per day compared to placebo (p=0.04). Positive trends were also observed in the annualized relapse rate (p=0.08) and number of relapses (p=0.10) among patients who completed the full first 12 months of treatment with 60 mg of MN-166 per day compared to those patients completing the first 12 months of treatment on placebo.

A significant reduction in brain volume loss (p=0.04), as measured by cranial magnetic resonance imaging (MRI) scans, was observed in patients treated with 60 mg per day of MN-166 compared to placebo. Loss of brain volume on MRI has been shown to correlate with clinical progression and disability in MS patients. Positive trends were also observed in several other radiological outcome measures, including the volume of gadolinium-enhancing (T1) lesions (p=0.09) in patients treated with 60 mg of MN-166 per day compared with placebo. However, no reduction in the cumulative number of active (gadolinium-enhancing (T1) and non-enhancing new/enlarging (T2)) lesions on crani
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:6/2/2015)... , June 2, 2015 ANI Pharmaceuticals, Inc. ... has received approval from the U.S. Food and Drug ... for Oxycodone Hydrochloride Oral Solution 5mg/5mL. Trailing twelve-month sales ... with three current competitors. ANI expects to begin shipping ... Przybyl , President and CEO of ANI Pharmaceuticals, stated, ...
(Date:6/2/2015)... June 2, 2015  PROMETRIKA, LLC, a full-service ... with the addition of pharmacovigilance services for clinical ... in safety data collection and reporting, as our ... professionals, and expert physicians, each with more than ... and monitoring of safety trends. ...
(Date:6/2/2015)... June 02, 2015 Research and Markets ... the "Electrophysiology Market by Product {Diagnostic Catheter ... Lab Devices (Mapping, Recording, Generator, ICE, X-ray)) & ... 2019" report to their offering. ... grow at a significant CAGR of 10.3% from ...
Breaking Medicine Technology:ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 2ANI Pharmaceuticals Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL 3PROMETRIKA Announces the Availability of Pharmacovigilance Services 2Global Electrophysiology Market Report 2015-2019 - Product, Ablation Catheter, Lab Devices & Indication Analysis 2Global Electrophysiology Market Report 2015-2019 - Product, Ablation Catheter, Lab Devices & Indication Analysis 3
... Feb. 27, 2012 Cardiac Science Corporation ... number of automated external defibrillators (AED) manufactured between July ... contain a component that may fail unexpectedly due to ... fail during a rescue attempt, the AED may not ...
... CLAREMONT, Calif., Feb. 27, 2012  The presidents of Chapman ... to establish a joint School of BioPharmacy, initially launching ... will focus on preparing graduate pharmacists for professions in ... modern pharmacy practice. The school will open in fall ...
Cached Medicine Technology:Cardiac Science Notifies AED Customers of Nationwide Voluntary Medical Device Correction 2Cardiac Science Notifies AED Customers of Nationwide Voluntary Medical Device Correction 3Cardiac Science Notifies AED Customers of Nationwide Voluntary Medical Device Correction 4Innovative School of BioPharmacy to Open in Fall 2014 2Innovative School of BioPharmacy to Open in Fall 2014 3
(Date:6/2/2015)... 02, 2015 Visiting Nurse Association ... of home health care, hospice and community services, ... CEO, Steve Landers, MD, MPH, to the Visiting ... , VNAA is a national association based ... mission driven, nonprofit providers of home and community-based ...
(Date:6/2/2015)... OH (PRWEB) June 02, 2015 Mercy ... ministry serving Ohio and Kentucky – has devoted the ... Well videos to skin cancer prevention. One in five ... video on Mercy Health’s YouTube channel, a Mercy Health ...     What are the main causes of skin cancer? , ...
(Date:6/2/2015)... First Choice Emergency Room , ... the United States, named Kenneth Alan Totz, D.O.as the ... facility. , “We are pleased to announce Dr. ... said Dr. James M. Muzzarelli, Executive Medical Director of ... his undergraduate degree from St. Edwards University in Austin, ...
(Date:6/2/2015)... Phoenix, AZ (PRWEB) June 02, 2015 ... Iowa community, has granted $70,000 to the UNMC to support ... NFL Kicker Billy Cundiff, a member of the Colleen’s Dream ... grant was the biggest to date for Colleen’s Dream ... Dr. Wang in Omaha. , “Dr. Wang is a rising ...
(Date:6/2/2015)... IL (PRWEB) June 02, 2015 While ... action adaptions of comic books, comic books themselves are ... , Comics Uniting Nations plans to produce educational comics ... forthcoming Global Goals for Sustainable Development - an international ... extreme poverty, hunger, health, education, sustainable energy, inequality, climate ...
Breaking Medicine News(10 mins):Health News:Steve Landers, MD, MPH, President and CEO of VNA Health Group Appointed to VNAA Board of Directors 2Health News:Steve Landers, MD, MPH, President and CEO of VNA Health Group Appointed to VNAA Board of Directors 3Health News:Video provides helpful information about skin cancer prevention 2Health News:First Choice Emergency Room Announces Dr. Kenneth Alan Totz as New Medical Director of Houston – Jones Road Facility 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3
... announced that they have created a computer tool ... microbicides// used by women for preventing HIV infections. ... infections globally are soaring. ,By applying ... a computer model that can predict the effectiveness ...
... Research Hospital have discovered that a protein called ABCB6 plays ... key to the ability// of red blood cells to carry ... cells to extract energy from nutrients. ,The St. ... membrane of the cell’s energy powerhouse called the mitochondria; and ...
... on par with other children from single births for ... has been found wanting and they fared less better ... twins receive less attention from parents as well as ... of 11,000 youngsters shows that twins are catching up. ...
... the good news: Suicide rates among younger and older Americans ... news: No one really knows why// . ,Those ... the University of South Carolina and released Thursday (Sept. 28) ... Health. ,Dr. Robert McKeown, a professor and associate ...
... by scientists at the Broad Institute of MIT and Harvard ... “roadmap” that can connect human diseases// with potential drugs to ... in human cells. Called the 'Connectivity Map,' the new tool ... of Science and in separate publications in the September 28 ...
... faculty members performing microsurgery in Tanzania from a computer ... experts// in Vietnam presenting an avian influenza patient to ... are some of the possible applications of a high-tech ... first time next week to link Johns Hopkins faculty ...
Cached Medicine News:Health News:Computer Tool Predicts Effectiveness Of Microbicides 2Health News:Computer Tool Predicts Effectiveness Of Microbicides 3Health News:ABCB6 Is Key to Production of Heme in Hemoglobin 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 3Health News:Genetic 'Roadmap' Charts Links Between Drugs and Human Disease 2Health News:Genetic 'Roadmap' Charts Links Between Drugs and Human Disease 3Health News:High-Speed Internet2 Link Revolutionizes Global Medical Education 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: